Drug Report History

Return to report

Below you will find the report version history. When a report is updated, a new version of the report is created. The report history allows you to see the changes between versions. You can select two versions of the report to compare. The fields that were changed between versions will be highlighted in yellow.

The translation of reports creates two separate versions which is why some reports may not seem to have any differences. In this case, only the language field below will be highlighted in yellow.

Version v6-FR Version v1-EN
Language French English
Date Updated 2022-06-13 2022-02-14
Drug Identification Number 02485370 02485370
Brand name JAMP RIVASTIGMINE JAMP RIVASTIGMINE
Common or Proper name Rivastigmine Hydrogen Tartrate Capsules Rivastigmine Hydrogen Tartrate Capsules
Company Name JAMP PHARMA CORPORATION JAMP PHARMA CORPORATION
Ingredients RIVASTIGMINE RIVASTIGMINE
Strength(s) 3MG 3MG
Dosage form(s) CAPSULE CAPSULE
Route of administration ORAL ORAL
Packaging size 100 100
ATC code N06DA N06DA
ATC description ANTI-DEMENTIA DRUGS ANTI-DEMENTIA DRUGS
Reason for shortage Disruption of the manufacture of the drug. Disruption of the manufacture of the drug.
Anticipated start date
Actual start date 2022-02-09 2022-02-09
Estimated end date 2022-05-20 2022-04-30
Actual end date 2022-05-30
Shortage status Resolved Actual shortage
Tier 3 Status No No
Company comments
Health Canada comments